Kieran J. Rothnie, PhD

Director Epidemiology
GSK
West Drayton, Uxbridge, United Kingdom

Kieran Rothnie has over 10 years of experience in Epidemiology and currently leads the inhaled and oral respiratory and classic and established product epidemiology team at GSK. Prior to joining GSK Kieran served in epidemiology and real world evidence positions at Brisol-Myers Squibb, Imperial College London and London School of Hygiene and Tropical Medicine.

Disclosure information not submitted.

Presentation(s):

• Applying the self-controlled case series to analyse safety endpoints in single-arm, open label extension studies: A case study of Belimumab for the treatment of systemic lupus erythematosus and risk of infection

  Monday, August 26, 2024
  1:30 PM – 1:45 PM CEST

• Using probabilistic bias analysis to account for outcome misclassification of COVID-19 death in pharmacoepidemiologic studies

  Tuesday, August 27, 2024
  1:15 PM – 1:30 PM CEST

• Framework for the application of Pharmacoepidemiology and Real-World Data analysis in Safety Signal Assessments

  Wednesday, August 28, 2024
  9:45 AM – 9:50 AM CEST